Blood Microbiota Dysbiosis Is Associated with the Onset of Cardiovascular Events in a Large General Population: The D.E.S.I.R. Study

Jacques Amar1,*, Céline Lange2,3, Gaëlle Payros4, Céline Garret4, Chantal Chabo1,4, Olivier Lantieri5, Michael Courtney6, Michel Marre7,8, Marie Aline Charles2,3, Beverley Balkau2,3, Rémy Burcelin1,4, for the D.E.S.I.R. Study Group†

1 INSERM U1048, Institute of Research on Metabolic and Cardiovascular Diseases, CHU Toulouse, Toulouse, France, 2 INSERM, CESP Centre for research in Epidemiology and Population Health, U1018, Epidemiology of Diabetes, Obesity and Chronic Kidney Disease Over the Lifecourse, Villejuif, France, 3 University Paris Sud 11, UMRs 1018, Villejuif, France, 4 Bio-Medical Research Federative Institute of Toulouse, Toulouse, France, 5 IRSAS, La Riche, France, 6 VAIOMER SAS, Toulouse, France, 7 Service d’endocrinologie-diabète-nutrition, Groupe Hospitalier Bichat-Claude Bernard, Assistance Publique des Hôpitaux de Paris, Paris, France, 8 INSERM U695, Université Denis Diderot Paris 7, Paris, France

Abstract

Aim: We recently described a human blood microbiome and a connection between this microbiome and the onset of diabetes. The aim of the current study was to assess the association between blood microbiota and incident cardiovascular disease.

Methods and Results: D.E.S.I.R. is a longitudinal study with the primary aim of describing the natural history of the metabolic syndrome and its complications. Participants were evaluated at inclusion and at 3-, 6-, and 9-yearly follow-up visits. The 16S ribosomal DNA bacterial gene sequence, that is common to the vast majority of bacteria (Eubac) and a sequence that mostly represents Proteobacteria (Pbac), were measured in blood collected at baseline from 3936 participants. 73 incident cases of acute cardiovascular events, including 30 myocardial infarctions were recorded. Eubac was lower (0.14±0.26 vs 0.12±0.29 ng/ml; P=0.02) whereas a non significant increase in Pbac was observed. In multivariate Cox analysis, Eubac was inversely correlated with the onset of cardiovascular complications, (hazards ratio 0.50 95% CI 0.35–0.70) whereas Pbac (1.56, 95%CI 1.12–2.15) was directly correlated.

Conclusion: Pbac and Eubac were shown to be independent markers of the risk of cardiovascular disease. This finding is evidence for the new concept of the role played by blood microbiota dysbiosis on atherothrombotic disease. This concept may help to elucidate the relation between bacteria and cardiovascular disease.

Citation: Amar J, Lange C, Payros G, Garret C, Chabo C, et al. (2013) Blood Microbiota Dysbiosis Is Associated with the Onset of Cardiovascular Events in a Large General Population: The D.E.S.I.R. Study. PLoS ONE 8(1): e54461. doi:10.1371/journal.pone.0054461

Editor: Antony Bayer, Cardiff University, United Kingdom

Received: October 7, 2012; Accepted: December 11, 2012; Published: January 25, 2013

Copyright: © 2013 Amar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The D.E.S.I.R. study has been supported by INSERM contracts with CNAMTS, Lilly, Novartis Pharma and Sanofi-Aventis; by INSERM (Réseaux en Santé Publique, Interactions entre les déterminants de la santé, Cohorte Santé TGR 2008), the Association Diabète Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS, Société Françophone du Diabète, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon. The funders of this study had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors received funding from commercial sources: Lilly, Novartis Pharma and Sanofi-Aventis, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche, Topcon. The funders of this study had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Introduction

Treatment of traditional cardiovascular risk factors has resulted in a dramatic decrease in the incidence of cardiovascular disease over the past 30 years [1,2]. Despite progress, cardiovascular disease remains the leading cause of mortality throughout the world, including in developed countries. More importantly, even in well treated and controlled high-risk cardiovascular patients, an important residual cardiovascular risk persists [3,4]. Beside the role of traditional risk factors, experimental and epidemiological evidence that infection is involved in the onset of atherosclerotic diseases continues to mount [5–11]. Interestingly, the role of gram negative bacteria on arterial wall structure and function has been studied. Wiederman et al [12] showed an association between endotoxemia and carotid atherosclerosis in a prospective population-based study. In line with this data, our group reported in a population-based study, a correlation between aortic stiffness and soluble CD14 blood level, the main endotoxin receptor [13]. A
randomized trial showed that a vaccination against gram negative bacteria resulted in aortic stiffening [14]. Furthermore, the presence of bacteria from intestinal or oral origin have been observed in atherosclerotic plaques and importantly, compared with oral and gut samples, atherosclerotic plaque contained significantly higher levels of Proteobacteria (Pbac) and fewer Firmicutes [15]. In this respect, we recently described a human blood microbiome [16]. As for gut microbiota, this result introduced the concept of tissue microbiota equilibrium as a potential factor in human health. Indeed, a body of evidence shows that gut microbiota dysbiosis plays a key role in various diseases such as type 1 diabetes [17], bowel diseases [18] and celiac disease [20]. For example, in inflammatory bowel diseases, reduced microbial diversity was observed [18]. Fecal samples from patients with celiac disease had lower proportions of Bifidobacterium and increased proportions of Bacteroides/Prevotella [20]. In the light of these data, rather than analyse the role of few selected pathogens, we sought to explore the effect of blood microbiota equilibrium on the onset of cardiovascular diseases in a general population, with a focus on proteobacteria phylum.

Methods

Population

D.E.S.I.R. (Data from an Epidemiological Study on the Insulin Resistance syndrome) is a longitudinal cohort study of 5,212 adults aged 30–65 years at baseline; the primary aim of the study was to describe the natural history of the metabolic syndrome [21]. Participants were recruited in 1994–1996 from ten Social Security Health Examination centers in central-western France, from volunteers insured by the French national social security system (80% of the French population - any employed or retired person and their dependents are offered free periodic health examinations). Equal numbers of men and women were recruited in five-year age groups. All participants gave written informed consent, and the study protocol was approved by the CCPPRB (Comité Consultatif de Protection des Personnes pour la Recherche Biomédicale) of the Hôpital Bicêtre (Paris, France). Participants were clinically and biologically evaluated at inclusion and at 3-, 6-, and 9-year follow-up visits. We excluded participants without data on the Pbac gene, Eubac gene, LDL-cholesterol, smoking, diabetes, hypertension or fibrinogen, and those who were likely to have infections: fibrinogen > 5 mg/l, abundant leucocyturia, taking antiviral therapy and extreme blood bacterial DNA levels.

Parameters Studied

The examining physician recorded the history of cardiovascular diseases and treatment for diabetes and hypertension. Smoking habits were documented in a self-administered questionnaire. Smokers were defined as those currently smoking ≥ 1 cig/day at inclusion or who quit smoking less than 3 years prior to the survey. Two measures of blood pressure were taken in a supine position after a 5 min rest; mean values were used. Participants were defined as having hypertension if they were treated for hypertension, or if their systolic/diastolic blood pressures were ≥ 140/90 mmHg. Weight and height were measured in lightly clad participants, and body mass index was calculated. The waist perimeter was measured horizontally at the smallest circumference between the lower rib and the iliac crests. Participants were followed until the end of the study or until a cardiovascular event occurred.

Primary outcome

The primary outcome was the first occurrence of a myocardial infarction (fatal or not), a diagnosis of myocardial ischemia and/or significant coronary stenosis determined either by coronary angiogram or scintigraphy, revascularization therapy or a cerebral infarction. These events were physician adjudicated by medical record review with information provided by treating physicians and hospitals, in participants who, on the follow-up questionnaires, reported new cardiovascular disease, chest pain, stroke, or leg pain when walking.

Biological Analyses

Blood was drawn after a 12-h fast. All biochemical measurements except bacterial DNA analysis were from one of four health center laboratories located in France at Blois, Chartres, La Riche, or Orleans. Fasting plasma glucose measured by the glucose oxidase method, was applied to fluoro-oxalated plasma using a Technicon RA100 (Bayer Diagnostics, Puteaux, France) or a Specific or a Delta device (Konelab, Evry, France). Total-cholesterol, HDL-cholesterol and triglycerides were measured by enzymatic methods; LDL-cholesterol was calculated from the Friedewald equation; fibrinogen was quantified by nephelometry and leucocytes by flow cytometry. Aspartate amino transferase (AST) and Alanine aminotransferase (ALT) activities were measured at 37°C with an automatic analyser (Technicon Dax 24; Bayer Diagnostics; or Lab 20 or Delta 60i; Konelab).

Proteobacteria phylum quantification within blood microbiota

The 16S ribosomal DNA bacterial gene sequences were measured in blood collected at baseline. We studied the 16S rDNA gene as some regions of this gene are highly conserved between different species of bacteria and it is considered a marker of the overall microbiota [22]. In addition to highly conserved primer binding sites, the 16S rDNA gene sequences contain hypervariable regions that can provide species-specific signature sequences useful for bacterial identification. The 16S ribosomal DNA gene sequence common to the vast majority of the bacteria phyla (Eubac) and the 16S rDNA sequences that belong to the Proteobacteria phylum (Pbac) were measured in blood at baseline. The 16S rDNA qPCR technique has been established as follows. Using both sets of primers (Eubac and Pbac) the efficacy of PCR amplification has been calculated against a pure E. coliBL21 DNA standard curve from 0.001 to 10 ng/μl and found linear (~95% efficacy). The rate of amplification was found close to 100%. It was calculated as well according to the following formula A = b2 where A is the expected amount of amplified DNA, b is the amount of DNA to be amplified, and n is the number of PCR cycles Similarly, the efficacy of PCR amplification for each sample has been established and found similar to that obtained for the standard curve. However, due to the large diversity of bacterial DNA in each sample, the rate of amplification could not be calculated precisely. This rate is expected to be better for Phac PCR than for Eubac, based on the dominance of the Proteobacteriacae family [16]. Therefore, the ratios obtained between Pbac and Eubac are expected to be higher than 1.

Bacterial DNA preparation

DNA was extracted from peripheral blood leukocytes using a classical phenol/chloroform extraction method followed by alcohol precipitation (ice-cold 70% alcohol). Air dried DNA was re-suspended in Tris EDTA and stored at ~80°C before use [23,24]. This method did not use glass microbeads to increase the
efficiency of bacterial DNA extraction, which is commonly employed in current methods, as at the time of sample preparation, the isolation of bacterial DNA was not the goal of the work. However, despite this important technical difference, we succeeded in amplifying 16S rDNA from blood. To validate the difference between these two extraction procedures, we extracted total blood DNA in the presence and in the absence of microbead. The efficacy of bacterial DNA extraction, as assessed by 16S rDNA qPCR amplification, was 10 times higher using microbead, although the absolute value of the bacterial DNA concentration was higher, the proportions between samples remained the same.

**Eubacteria quantitation**

Total DNA concentration was determined using the Quant-iT™ dsDNA Broad-Range Assay Kit (Invitrogen). The mean concentration was 121.1±208.3 ng/µl. Each sample was diluted ten-fold in Tris buffer EDTA. The DNA was amplified by real-time PCR (Stepone; Applied Biosystems) in optical grade 96-well plates. The PCR reaction was performed in a total volume of 25 µl using the Power SYBR® Green PCR master mix (Applied Biosystems), containing 300 nM of each of the universal forward and reverse primers eubac-F (‘-TCCTACGGGAGGCAGCAGTG-3’) and eubac-R (‘-GGACTACCAGGGTATCTTAATCTCCTGT-3’). The reaction conditions for amplification of DNA were 95°C for 10 min and 35 cycles of 95°C for 15 s and 60°C for 1 min. The amplification step was followed by a melting curve step according to the manufacturer’s instructions (from 60°C to 90°C) to determine the specificity of the amplification product obtained. The amount of amplified DNA was determined using a standard curve obtained by real time PCR from dilutions ranging from 0.001 to 10 ng/µl of E. coli BL21 total DNA.

**Proteobacteria quantitation**

The DNA coding the 16S rDNA was amplified as described above using forward and reverse primers Proteobac-F (F-Bact1369) (‘-CGGTGAATACGTTCCCGG-3’) and Proteobac-R (R-Prok1492) (‘-TACGGGTACCTTGTTACGACTT-3’) as described by Valladares et al [25]. These primers amplify a subset of 16S rDNA which corresponds mostly to Proteobacteria as described by Valladares et al [25]. These primers amplify a subset of 16S rDNA which corresponds mostly to Proteobacteria as described by Valladares et al [25]. The linearity of the relations with Eubac and Pbac were higher in those with incident cardiovascular events as compared with controls.

**Prediction of acute cardiovascular events and microbiota**

We recorded 73 incident cases of acute cardiovascular events, including 30 myocardial infarctions (2 fatal), 26 with revascularization therapy, 11 significant myocardial ischemia diagnosed either by coronarography or scintigraphy and 6 cranial infarctions during an average follow-up time of 101±22 months. Eubac was significantly lower in patients destined to have cardiovascular events. A non significant increase in Phac concentration was also observed (Table 1). In multivariate Cox model analysis, after adjustment for confounders, Eubac was negatively correlated with primary outcome (Figure 2). A 3.7 fold increase in the risk of cardiovascular events was observed between volunteers who had the lowest levels of Eubac and the highest level of Phac as compared with those who had the highest levels of Eubac and the lowest level of Phac (P for trend 0.003).

**Discussion**

The main finding of the study is that a dysbiosis in blood microbiota, defined by a decrease in blood bacterial DNA content and an increase in the proportion of Proteobacteria phylum within blood microbiota, predicts long-term cardiovascular prognosis. Since this study is the first to raise this concept, confirmatory study is required.

Until now, most of the epidemiological evidence that supports a relation between infection and cardiovascular events is based on associations between circulating antibacterial antibodies and cardiovascular diseases [7,10]. For example, it has been shown that antibodies against oral pathogens were correlated either with
Table 1. Characteristics of the D.E.S.I.R. study population, mean ± SD, geometric *SD or n(%), according to presence of incident cardiovascular events during the 9 year follow-up.

|                          | Free of cardiovascular events | With cardiovascular events | P     |
|--------------------------|------------------------------|-----------------------------|-------|
|                          | (n = 3863)                   | (n = 73)                    |       |
| Men (n (%))              | 1895 (49)                   | 65 (89)                     | <0.0001|
| Age (years)              | 47±10                       | 55±8                        | <.0001 |
| Body mass index (kg/m²)  | 24.6±3.7                    | 26.8±3.7                    | <.0001 |
| Waist perimeter (cm)     | 83±11                       | 93±12                       | <.0001 |
| Systolic blood pressure (mm Hg) | 131±15                  | 144±17                      | <.0001 |
| Diastolic blood pressure (mm Hg) | 80±9                     | 86±10                       | <.0001 |
| Total cholesterol (mmol/l) | 5.71±0.99                  | 6.21±1.07                   | <.0001 |
| HDL-cholesterol (mmol/l) | 1.64±0.43                   | 1.38±0.37                   | <.0001 |
| LDL-cholesterol (mmol/l) | 3.58±0.90                   | 4.13±0.91                   | <.0001 |
| Triglycerides (mmol/l) * | 0.97±0.67                   | 1.35±1.65                   | <.0001 |
| Fasting blood glucose (mmol/l) | 5.34±0.77                 | 6.13±1.98                   | <.0001 |
| Fibrinogen (g/l)         | 2.99±0.65                   | 3.15±0.60                   | 0.04  |
| Leukocytes (10⁹/l)       | 6.36±1.71                   | 7.14±1.95                   | 0.0001 |
| Aspartate aminotransferase (UI/l) | 20.50±9.87              | 24.12±12.04                | 0.002 |
| Alanine aminotransferase (UI/l) | 25.63±16.88              | 32.75±21.07                | 0.0004 |
| Eubac gene (ng/µl) *     | 0.07±2.86                   | 0.05±3.06                   | 0.02  |
| Pbac gene (ng/µl) *      | 0.20±4.34                   | 0.22±5.18                   | 0.7   |
| Current smokers (n (%))  | 984 (25)                    | 27 (37)                     | 0.03  |
| Hypertension (n (%))     | 1391 (36)                   | 52 (71)                     | <0.0001|
| Diabetes (n (%))         | 84 (2)                      | 13 (18)                     | <0.0001|

*Log transformed for analysis.

Eubac denotes 16S ribosomal DNA gene sequences, common to the vast majority of the bacteria phyla.
Pbac denotes 16S ribosomal DNA gene sequences that belongs to the Proteobacteria phylum.

doi:10.1371/journal.pone.0054461.t001

Figure 1. Proteobacteria phylum within blood microbiota. Box and whisker plot, showing medians (dot in middle of box, quartiles at end of box, and as whiskers the extremes), of Eucbacteria: 16S ribosomal DNA gene sequences common to the vast majority of bacteria phyla (Eubac) according to Pbac: 16S ribosomal DNA sequences that belong to the Proteobacteria phylum (both variables are log transformed).
doi:10.1371/journal.pone.0054461.g001
target organ damage [26] or with the onset of cardiovascular events [27]. Based on this indirect approach, various pathogens were identified as predictors of cardiovascular diseases. Also, the presence of pathogens within plaque has been previously established [28], in coronary lesions as well: using human specimens obtained during coronary atherectomy, the “fingerprints” of more than 50 different bacterial species have been observed [29]. Therefore, it seems unlikely that a single pathogen is a key for the onset of cardiovascular events [30]. In addition to these results, our findings show that beyond the diversity of pathogens associated with cardiovascular diseases, tissue microbiota equilibrium could be involved in the mechanism underlying the relation between infection and atherosclerotic events.

The concept of microbiota dysbiosis as a key player in the course of various diseases has been proposed for gut [31–33] and oral microbiota [34,35]. Changes in gut microbiota equilibria

Table 2. Major cardiovascular risk factors by tertiles of Eubacteria (Eubac).

| Tertiles of Eubac | ≤0.039 ng/µL | 0.040 to 0.093 ng/µL | >0.093 ng/µL | P trend |
|------------------|--------------|----------------------|--------------|---------|
|                  | n = 1299     | n = 1338             | n = 1299     |         |
| Men (n (%))      | 638 (49)     | 652 (49)             | 670 (52)     | 0.1     |
| Age (years)      | 46±10        | 47±10                | 48±10        | 0.0002  |
| Body mass index (kg/m²) | 24.7±3.7   | 24.6±3.7             | 24.6±3.5     | 0.5     |
| Waist perimeter (cm) | 83±12       | 83±12                | 83±11        | 0.6     |
| Systolic blood pressure (mm Hg) | 131±15      | 130±15               | 132±16       | 0.06    |
| Diastolic blood pressure (mm Hg) | 80±9         | 79±9                 | 81±10        | 0.008   |
| Total cholesterol (mmol/l) | 5.74±0.98    | 5.73±0.97            | 5.71±0.97    | 0.3     |
| HDL-cholesterol (mmol/l) | 1.62±0.43    | 1.66±0.43            | 1.61±0.42    | 0.01    |
| LDL-cholesterol (mmol/l) | 3.60±0.91    | 3.58±0.90            | 3.58±0.90    | 0.3     |
| Fasting blood glucose (mmol/l) | 5.39±0.82    | 5.34±0.69            | 5.34±0.91    | 0.03    |
| Fibrinogen (g/l) | 2.93±0.58    | 2.95±0.60            | 3.12±0.74    | 0.0001  |
| Aspartate aminotransferase (UI/l) | 20.65±9.44  | 20.65±9.55           | 20.39±10.74  | 0.74    |
| Alanine aminotransferase (UI/l) | 25.19±15.55  | 25.43±17.56          | 26.67±17.74  | 0.06    |
| Current smokers (n (%)) | 382 (29)    | 321 (24)             | 308 (24)     | 0.0004  |
| Diabetes (n (%)) | 30 (2)       | 29 (2)               | 38 (3)       | 0.2     |

doi:10.1371/journal.pone.0054461.t002

Table 3. Major cardiovascular risk factors by tertiles of Proteobacteria (Pbac).

| Tertiles of Pbac | ≤0.095 ng/µL | >0.095 to <0.33 | ≥0.33 ng/µL | P trend |
|------------------|--------------|-----------------|-------------|---------|
|                  | n = 1299     | n = 1338        | n = 1299    |         |
| Men (n (%))      | 640 (49)     | 648 (48)        | 672 (52)    | 0.1     |
| Age (years)      | 47±10        | 47±10           | 48±10       | 0.01    |
| Body mass index (kg/m²) | 24.8±3.8     | 24.5±3.6        | 24.7±3.7    | 0.3     |
| Waist perimeter (cm) | 83±12        | 83±11           | 84±12       | 0.8     |
| Systolic blood pressure (mm Hg) | 131±15       | 130±15          | 132±16      | 0.01    |
| Diastolic blood pressure (mm Hg) | 80±9         | 79±9            | 81±10       | 0.002   |
| Total cholesterol (mmol/l) | 5.74±0.98    | 5.73±0.97       | 5.71±0.97   | 0.4     |
| HDL-cholesterol (mmol/l) | 1.63±0.43    | 1.64±0.42       | 1.62±0.43   | 0.4     |
| LDL-cholesterol (mmol/l) | 3.60±0.91    | 3.58±0.90       | 3.58±0.90   | 0.5     |
| Fasting blood glucose (mmol/l) | 5.39±0.82    | 5.34±0.69       | 5.34±0.91   | 0.2     |
| Fibrinogen (g/l) | 2.93±0.58    | 2.95±0.60       | 3.12±0.74   | 0.0001  |
| Aspartate aminotransferase (UI/l) | 20.80±9.72   | 20.00±8.60      | 20.90±11.29 | 0.04    |
| Alanine aminotransferase (UI/l) | 25.15±15.85  | 24.22±14.60     | 27.56±19.96 | <.0001  |
| Current smokers (n (%)) | 362 (28)     | 353 (26)        | 296 (23)    | 0.001   |
| Diabetes (n (%)) | 30 (2)       | 26 (2)          | 41 (3)      | 0.08    |

doi:10.1371/journal.pone.0054461.t003
operate on pathological processes, either systematically through inflammatory mediators or locally. For example obesity has been associated with inflammation gut-mediated microbiota dysbiosis [36] whereas in inflammatory bowel disease, gut microbiota dysbiosis impacts on bile acid modification, which in turn has a direct deleterious effect on the disease [37]. To the best of our knowledge, our results are the first to show that microbiota dysbiosis is a player in pathological processes in cardiovascular disease.

This new paradigm may help to elucidate the relation between bacteria and cardiovascular disease. Indeed, whereas the aforementioned evidence supports the role of various pathogens, most interventional trials aiming to test antibiotics targeting these pathogens in the treatment of atherosclerosis, failed to improve cardiovascular prognostic [38]. In this respect, the resilience of the microbial community to a short-course antibiotic challenge has been repeatedly established [39,40]. For example, in healthy volunteers the fecal microbiota showed a major shift in dominant species on antibiotic treatment, starting 24 h after treatment initiation. Within 30 days following antibiotic treatment, the fecal microbiota had an average similarity of 88% to baseline. It is likely that this resilience exists within human tissue and may contribute to explain the failure of antibiotic therapy administered over a short period of time, to prevent cardiovascular events. However, it seems possible to cause a shift to an alternative stable state. For example, the effect of repeated antibiotic perturbations have been tested in humans and it has been show that as soon as one week after the end of each course of antibiotics, gut microbiota begin to return to their initial state, but the return was often incomplete [41]. Taken together, these data may help to design some new interventional trials targeting tissue microbiota dysbiosis to prevent cardiovascular diseases.

Surprisingly, we observed a negative correlation between blood bacterial DNA as a whole or proteobacteria DNA and current smoking. In this respect, no change in lipopolysaccharide (LPS) concentration has been observed in an intervention trial [42] after cigarette smoking. Furthermore, no difference in blood LPS concentration has been found in current smokers as compared with non-smokers [43]. At this stage, no firm conclusion can be drawn from our current results. We can only hypothesize that an important change in tissue microbiota should be associated with current smoking. Importantly, we failed to find consistent relations between blood bacterial DNA and lipoprotein levels suggesting

| Table 4. Standardized hazards ratios for an incident cardiovascular outcome. |
|-----------------|-----------------|-----------------|
| Hazard ratio(95% CI) | P value |
| Eubac | 0.68 (0.53–0.88) | 0.004 |
| Pbac | 0.50 (0.35–0.70) | <0.0001 |

Models 1 and 2 were adjusted for gender, smoking status, LDL-cholesterol, fibrinogen, hypertension and diabetes. In addition, in model 2 Pbac was included.

doi:10.1371/journal.pone.0054461.t004
that these lipoproteins did not play a major role on blood bacterial DNA burden. Also, with respect to the body of evidence supporting a link between non-alcoholic fatty liver disease [44] and cardiovascular prognosis, we showed a positive correlation between Eubac and Phac and ALT raising the interesting hypothesis of tissue microbiota dysbiosis as a common soil for non-alcoholic steatosis hepatitis and cardiac diseases.

In conclusion, our study demonstrates for the first time, that a microbiota dysbiosis predicts acute cardiovascular events in a large general population. This innovative concept opens new ways to predict and perhaps even prevent cardiovascular diseases.

Acknowledgments

The D.E.S.I.R. Study Group: INSERM CESP U1018: B Balkau, P Ducimetière, E Escrègue; INSERM U367: F Ahlenc-Gelas; CHU d’Angers: A Girault; Bichat Hospital: F Fumerton, M Marre, R Roussel; CHU de Rennes: F Bonnet; Centre National de la Recherche Scientifique UMR 8090, Lille: S, Cauchi, F Frouge; Institut de Recherche Médicale Générale: J Cogneau; Inter-Regional pour la Santé: C Born, E Cacas, N Copin, JG Moreau, O Lantiert, F Rakotozafy, J Tchiel, and S Vol.

Author Contributions

Conceived and designed the experiments: JA RB BB. Performed the experiments: CL GF CG CC. Analyzed the data: OL MM MMC MAC. Wrote the paper: JA CL RB MM BB.

References

1. Carandang R, Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, et al. (2006) Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA 296: 2939–2946.
2. Yeh RW, Sidney S, Chandra M, Sorel M, Sehby JV, et al. (2010) Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362: 2153–2163.
3. Blacher J, Evans A, Avarel D, Amouyal P, Ferrières J, et al. (2004) PRIME Study Group. Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidemia in the population: the PRIME study. J Hypertens 22: 415–421.
4. Hellmann M, Buckley DL, Freeman M, Fu R, Rogers K, et al. (2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 151:496–497.
5. Gilbert A, Lion G (1889) Arterie´rites infectieuses expe´rimentales. Comptes Rendus Hebdomadaires des Sciences et Memoires de la Socie´te´ de Biologie 41: 583–584.
6. Maas M, Bartels C, Engel PM, Mamat U, Sievers HH (1998) Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 15: 827–832.
7. Espinola-Klein C, Kupperth HJ, Blankenberg S, Bickel C, Kopp H, et al. (2002) AtheroGene Investigators. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 105: 15–21.
8. Madjil M, Naghavi M, Litovsky SA, Cessells SW (2003) Inflammation and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation 108:2790–6.
9. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351: 2611–2618.
10. Passinen P, Nyüssinen K, Allihan G, Salonen R, Lasukainen JA, et al. (2005) Serum antibody levels to Actinobacillus actinomycetemcomitans predict the risk for coronary heart disease. Arterioscler Thromb Vasc Biol 25:433–438.
11. Wang Z, Klipfell E, Bennett BJ, Levison BS, et al. (2011) Gut flora DNA burden. Also, with respect to the body of evidence for a concept. Diabetologia 54:3055–3061.
12. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, et al. (2011) Gut flora microbiota dysbiosis predicts acute cardiovascular events in a large general population. This innovative concept opens new ways to predict and perhaps even prevent cardiovascular diseases.

Blood Microbiota Dysbiosis and Cardiac Events

In conclusion, our study demonstrates for the first time, that a microbiota dysbiosis predicts acute cardiovascular events in a large general population. This innovative concept opens new ways to predict and perhaps even prevent cardiovascular diseases.

Acknowledgments

The D.E.S.I.R. Study Group: INSERM CESP U1018: B Balkau, P Ducimetière, E Escrègue; INSERM U367: F Ahlenc-Gelas; CHU d’Angers: A Girault; Bichat Hospital: F Fumerton, M Marre, R Roussel; CHU de Rennes: F Bonnet; Centre National de la Recherche Scientifique UMR 8090, Lille: S, Cauchi, F Frouge; Institut de Recherche Médicale Générale: J Cogneau; Inter-Regional pour la Santé: C Born, E Cacas, N Copin, JG Moreau, O Lantiert, F Rakotozafy, J Tchiel, and S Vol.

Author Contributions

Conceived and designed the experiments: JA RB BB. Performed the experiments: CL GF CG CC. Analyzed the data: OL MM MMC MAC. Wrote the paper: JA CL RB MM BB.
40. Dethlefsen L, Huse S, Sogin ML, Relman DA (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 6:e280.

41. Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108 Suppl 1:4554–4561.

42. Erridge C, Attina T, Spickett CM, Webb DJ (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86:1286–92.

43. Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W (1999) Bacterial endotoxin is an active component of cigarette smoke. Chest 115:829–835.

44. Bonora E, Targher G (2012) Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 9: 372–81.